A carregar...
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...
Na minha lista:
| Publicado no: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4722889/ https://ncbi.nlm.nih.gov/pubmed/26503698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4314 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|